BiotechTube

Ramucirumab + Placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatocellular Carcinoma

Conditions

Hepatocellular Carcinoma

Trial Timeline

Jul 20, 2015 → Nov 19, 2021

NCT ID
NCT02435433

About Ramucirumab + Placebo

Ramucirumab + Placebo is a phase 3 stage product being developed by Eli Lilly for Hepatocellular Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02435433. Target conditions include Hepatocellular Carcinoma.

What happened to similar drugs?

5 of 20 similar drugs in Hepatocellular Carcinoma were approved

Approved (5) Terminated (2) Active (14)
✅LenvatinibEisaiApproved
✅Epirubicin + lipiodolJohnson & JohnsonApproved
✅Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty OintmentBayerApproved
✅Xenetix-CT perfusion imagingGuerbetApproved
✅Gadoterate meglumineGuerbetApproved
🔄Atezolizumab + Bevacizumab + TiragolumabChugai PharmaceuticalPhase 3
🔄Tivantinib + PlaceboDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02435433Phase 3Completed
NCT00917384Phase 3Completed

Competing Products

20 competing products in Hepatocellular Carcinoma

See all competitors
ProductCompanyStageHype Score
CT-01 + EVEROLIMUSCaptor TherapeuticsPhase 1
26
ateganosine + CadonilimabMAIA BiotechnologyPhase 1
26
ERY974 + Tocilicumab + Atezolizumab + BevacizumabChugai PharmaceuticalPhase 1
33
Atezolizumab + Bevacizumab + TiragolumabChugai PharmaceuticalPhase 3
44
GC33(RO5137382) + SorafenibChugai PharmaceuticalPhase 1
29
CS-1008 2 mg/kg + Sorafenib + CS-1008 6/2 mg/kg + CS-1008 6/6 mg/kg + CS-1008 4 mg/kg + CS-1008 6 mg/kgDaiichi SankyoPhase 2
35
Tivantinib + PlaceboDaiichi SankyoPhase 3
40
OSI-906 + PlaceboAstellas PharmaPhase 2
27
Enzalutamide + PlaceboAstellas PharmaPhase 2
35
Enzalutamide + Enzalutamide with SorafenibAstellas PharmaPhase 1
29
Recombinant oncolytic virus M1, anti PD-1 antibody, ApatinibSun PharmaceuticalPhase 1
25
Irinotecan + Sonidegib + SorafenibSun PharmaceuticalPhase 2
42
mFOLFOX7 combined with Camrelizumab and apatinibSun PharmaceuticalPhase 2
42
camrelizumab& apatinibSun PharmaceuticalPhase 2
31
LenvatinibEisaiPre-clinical
26
Lenvatinib PillEisaiPhase 2
39
Sorafenib + SorafenibEisaiPhase 1/2
32
LenvatinibEisaiPhase 2
42
Lenvatinib + NivolumabEisaiPhase 2
35
H3B-6527EisaiPhase 1
29